



COPY OF PAPERS  
ORIGINALLY FILEDPlease type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)

RECEIVED

Substitute for Form 1449A/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as needed)				Complete If Known	
				Application Number	10/086,208
				Filing Date	February 28, 2002
				First Named Inventor	Gideon Goldstein
				Group Art Unit	1648
				Examiner Name	J. Parkin
Sheet	1	of	7	Attorney Docket Number	GGP2CUSA

U.S. PATENT DOCUMENTS						
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
	AA	4,871,488	B1	R. Mannino	10/03/1989	
	AB	5,019,510	B1	S. Wain-Hobson	05/28/1991	
	AC	5,110,802	B1	E. Cantin	05/05/1992	
	AD	5,158,877	B1	R. Edwards	10/27/1992	
	AE	5,238,822	B1	C. Dykes	08/24/1993	

FOREIGN PATENT DOCUMENTS								
Examiner Initials <sup>2</sup>	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>4</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>3</sup> (if known)				
	AL	WO	WO87/02989	A1	A. Aldovinni	05/21/1987		
	AM	WO	WO91/09958	A2	A. Frankel	07/11/1991		
	AN	WO	WO91/10453	A1	J. Lisiewicz	07/25/1991		
	AO	WO	WO92/07871	A1	M. Sumner-Smith	05/14/1992		
	AP	WO	WO92/14755	A1	E. Ruoslahti	09/03/1992		

Examiner Signature		Date Considered	09/06/03
--------------------	--	-----------------	----------


\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.



COPY OF PAPERS  
- ORIGINALLY FILED



Please type a plus sign (+) inside this box → ☐


PTO/SB/08A (08-00)

<b>Substitute for Form 1449A/PTO</b> <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary) 				<b>Complete if Known</b>	
				Application Number	10/086,208
				Filing Date	February 28, 2002
				First Named Inventor	Gideon Goldstein
				Group Art Unit	1648
				Examiner Name	J. Parkin
Sheet	2	of	7	Attorney Docket Number	GGP2CUSA

RECEIVED  
MAY 03 2002  
TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS						
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
	AF	5,597,895	B1	R. Gaynor	01/28/1997	
	AG	5,606,026	B1	T. Rodman	02/25/1997	
	AH	5,674,980	B1	A. Frankel	10/07/1997	
	AI	5,891,994	B1	G. Goldstein	04/06/1999	
	AJ	6,193,981	B1	G. Goldstein	02/27/2001	

FOREIGN PATENT DOCUMENTS								
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
	AQ	WO	WO95/31999	A1	G. Goldstein	11/30/1995		
	AAL	WO	WO99/02185	A1	G. Goldstein	01/21/1999		

Examiner Signature		Date Considered	09/08/03
--------------------	---	-----------------	----------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

COPY OF PAPERS  
ORIGINALLY FILEDPlease type a plus sign (+) inside this box → ☐

PTO/SB/08B (08-00)

Substitute for Form 1449/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)		COMPLETE MAY 01 2002 PATENT & TRADEMARK OFFICE		Complete If Known	
		Application Number	10/086,208		
		Filing Date	February 28, 2002		
		First Named Inventor	Gideon Goldstein		
		Group Art Unit	1648		
		Examiner Name	J. Parkin		
Sheet	3	of	7	Attorney Docket Number	GGP2CUSA

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiners Initials <sup>1</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
7	AR	A. ALDOVINI et al, "Synthesis of the Complete Trans-Activation Gene Product of Human T-Lymphotropic Virus Type III in Escherichia coli: Demonstration of Immunogenicity in vivo and Expression in vitro", Proc. Natl. Acad. Sci. USA, 83:6672-6676 (September, 1986)	
	AS	C. BAUMBERGER et al, "High Levels of Circulating RNA in Patients with Symptomatic HIV-1 Infection", AIDS, 7(Suppl. 2):S59-S64 (November, 1993)	
	AT	D. BRAKE et al, "Characterization of Murine Monoclonal Antibodies to the tat Protein from Human Immunodeficiency Virus Type 1", J. Virol., 64(2):962-965 (February, 1990)	
	AU	M. CLERICI et al, "T-Cell Proliferation to Subinfectious SIV Correlates with Lack of Infection after Challenge of Macaques", AIDS, 8(10):1391-1395 (October, 1994)	
	AV	R. COOMBS et al, "Association of Plasma Human Immunodeficiency Virus Type 1 RNA Level with Risk of Clinical Progression in Patients with Advanced Infection", J. Infect. Dis., 174:704-712 (October, 1996)	
	AW	M. DANIEL et al, "Protective Effects of a Live Attenuated SIV Vaccine with a Deletion in the nef Gene", Science, 258:1938-1941 (December 18, 1992)	
	AX	S. FAWELL et al, "Tat-Mediated Delivery of Heterologous Proteins into Cells", Proc. Natl. Acad. Sci. USA, 91:664-668 (January, 1994)	
	AY	A. FRANKEL et al, "Activity of Synthetic Peptides from the Tat Protein of Human Immunodeficiency Virus Type 1", Proc. Natl. Acad. Sci. USA, 86:7397-7401 (October, 1989)	

Examiner Signature	Date Considered	09/04/03
--------------------	-----------------	----------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

COPY OF PAPERS  
ORIGINALLY FILED

# 3-4

Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (08-00)

RECEIVED

Substitute for Form 1449A/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)				Complete If Known	
				Application Number	10/086,208
				Filing Date	February 28, 2002
				First Named Inventor	Gideon Goldstein
				Group Art Unit	1648
				Examiner Name	J. Parkin
Sheet	4	of	7	Attorney Docket Number	GGP2CUSA

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiners Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
Y	AZ	G. GOLDSTEIN, "HIV-1 Tat Protein as a Potential AIDS Vaccine", Nature Medicine, 2(9):960-964 (September, 1996)	
	AAR	B. HAYNES, "Scientific and Social Issues of Human Immunodeficiency Virus Vaccine Development", Science, 260:1279-1286 (May 28, 1993)	
	AAS	W. KRONE et al, "Natural Antibodies to HIV-tat Epitopes and Expression of HIV-1 Genes in Vivo", J. Med. Virol., 26:261-270 (November, 1988)	
	AAT	K. KUSUMI et al, "Human Immunodeficiency Virus Type 1 Envelope Gene Structure and Diversity in vivo and after Cocultivation in vitro", J. Virol., 66(2):875-885 (February, 1992)	
	AAU	B. LARDER et al, "HIV with Reduced Sensitivity to Zidovudine (AZT) Isolated During Prolonged Therapy", Science, 243:1731-1733 (March 31, 1989)	
	AAV	T-H. LEE et al, "Circulating HIV-1-Infected Cell Burden from Seroconversion to AIDS: Importance of Postseroconversion Viral Load on Disease Course", J. Acq. Imm. Def. Synd., 7(4):381-388 (April, 1994)	
	AAW	N. LETVIN, "Vaccines Against Human Immunodeficiency Virus - Progress and Prospects", N. Engl. J. Med., 329(19):1400-1405 (November 4, 1993)	
	AAX	D. MANN et al, "Endocytosis and Targeting of Exogenous HIV-1 Tat Protein", EMBO J., 10(7):1733-1739 (July, 1991)	
Y	AAZ	J. MELLORS et al, "Prognosis in HIV-1 Infection Predicted by the Quantity of Virus in Plasma", Science, 272:1167-1170 (May 24, 1996)	

Examiner Signature	Date Considered
	07/06/02

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

#3-5

Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (08-00)

Substitute for Form 1449A/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)			Complete if Known		
			Application Number	10/086,208	
			Filing Date	February 28, 2002	
			First Named Inventor	Gideon Goldstein	
			Group Art Unit	1648	
			Examiner Name	J. Parkin	
Sheet	5	of	7	Attorney Docket Number	GGP2CUSA

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiners Initials <sup>*</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
8	AAZ	A. MEYERHANS et al, "Temporal Fluctuations in HIV Quasispecies in vivo are not Reflected by Sequential HIV Isolations", Cell, 58:901-910 (September 8, 1989)	
	BR	J. OSBORN, "The Rocky Road to an AIDS Vaccine", J. Acq. Imm. Def. Syndr. Hum. Retrovirol., 9(1):26-29 (May, 1995)	
	BS	W. PAUL, "Can the Immune Response Control HIV Infection?", Cell, 82:177-182 (July 28, 1995)	
	BT	B. PRESTON et al, "Fidelity of HIV-1 Reverse Transcriptase", Science, 242:1168-1171 (November 25, 1988)	
	BU	M. RE et al, "Effect of Antibody to HIV-1 Tat Protein on Viral Replication in Vitro and Progression of HIV-1 Disease in Vivo", J. Acq. Imm. Def. Synd. Hum. Retrovirol., 10(4):408-416 (December 1, 1995)	
	BV	J. ROBERTS et al, "The Accuracy of Reverse Transcriptase from HIV-1", Science, 242:1171-1173 (November 25, 1988)	
	BW	M. SAAG et al, "Hiv Viral Load Markers in Clinical Practice", Nature Medicine, 2(6):625-629 (June, 1996)	
	BX	M. SAAG et al, "A Short-Term Clinical Evaluation of L-697,661, a Non-Nucleoside Inhibitor of HIV-1 Reverse Transcriptase", N. Engl. J. Med., 329(15):1065-1072 (October 7, 1993)	
✓	BY	K. SAKSELA et al, "Human Immunodeficiency Virus Type 1 mRNA Expression in Peripheral Blood Cells Predicts Disease Progression Independently of the Numbers of CD4+ Lymphocytes", Proc. Natl. Acad. Sci. USA, 91:1104-1108 (February, 1994)	

Examiner Signature		Date Considered	07/08/03
--------------------	--	-----------------	----------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

#3-6

COPY OF PAPERS  
ORIGINALLY FILEDPlease type a plus sign (+) inside this box → ☐

PTO/SB/08B (08-00)

Substitute for Form 1449/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)				Complete if Known	
				Application Number	10/086,208
				Filing Date	February 28, 2002
				First Named Inventor	Gideon Goldstein
				Group Art Unit	1648
				Examiner Name	J. Parkin
Sheet	6	of	7	Attorney Docket Number	GGP2CUSA

## OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiners Initials <sup>1</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
J	BZ	M. SANDE et al, "Antiretroviral Therapy for Adult HIV-Infected Patients", JAMA, 270(21):2583-2589 (December 1, 1993)	
	BBR	M. SELIGMANN et al, "Concorde: MRC/ANRS Randomised Double-Blind Controlled Trial of Immediate and Deferred Zidovudine in Symptom-free HIV Infection", Lancet, 343:871-881 (April 9, 1994)	
	BBS	L. STEINAA et al, "Antibody to HIV-1 Tat Protein Inhibits the Replication of Virus in Culture", Arch. Virol., 139:263-271 (1994)	
	BBT	K. SUZUE et al, "Adjuvant-Free hsp70 Fusion Protein System Elicits Humoral and Cellular Immune Responses to HIV-1 p24", J. Immunol., 156:873-879 (January 15, 1996)	
	BBU	J. TAM, "Synthetic Peptide Vaccine Design: Synthesis and Properties of a High-Density Multiple Antigenic Peptide System", Proc. Natl. Acad. Sci. USA, 85:5409-5413 (August, 1988)	
	BBV	B. TINDALL et al, "Primary HIV Infection: Host Responses and Intervention Strategies", AIDS, 5(1):1-14 (January, 1991)	
	BBW	S. WELLES et al, "Prognostic Value of Plasma Human Immunodeficiency Virus Type 1 (HIV-1) RNA Levels in Patients with Advanced HIV-1 Disease and with Little or No Prior Zidovudine Therapy", J. Infect. Dis., 174:696-703 (October, 1996)	
	BBX	S. WOLINSKY et al, "Adaptive Evolution of Human Immunodeficiency Virus-Type 1 During the Natural Course of Infection", Science, 272:537-542 (April 26, 1996)	

Examiner Signature	Date Considered
	09/06/03

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


<sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

#3-7

**COPY OF PAPERS  
ORIGINALLY FILED**

Please type a plus sign (+) inside this box → +

PTO/SB/08B (08-00)

Substitute for Form 1449 A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)						
				<b>Complete If Known</b>		
				Application Number	10/086,208	
				Filing Date	February 28, 2002	
				First Named Inventor	Gideon Goldstein	
				Group Art Unit	1648	
Examiner Name				J. Parkin		
Sheet	7	of	7	Attorney Docket Number		GGP2CUSA

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiners Initials <sup>1</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
BBY		G. ZAULI et al, "An Autocrine Loop of HIV Type-1 Tat Protein Responsible for the Improved Survival/Proliferation Capacity of Permanently Tat-Transfected Cells and Required for Optimal HIV-1 LTR Transactivating Activity", J. Acq. Imm. Def. Synd. Hum. Retrovirol., 10(3):306-316 (November 1, 1995)	
BBZ		Webster's Ninth New Collegiate Dictionary, p. 602 (1990)	
CR		D. MCPHEE et al, "Recognition of Envelope and tat Protein Synthetic Peptide Analogs by HIV Positive Sera or Plasma", FEBS Letters, 233(2):393-396 (June, 1988)	
CS		C. LI et al, "Tat Protein Induces Self-Perpetuating Permissivity for Productive HIV-1 Infection", Proc. Natl. Acad. Sci. USA, 94:8116-8120 (July, 1997)	
CT		D. BRAKE et al, "Characterization of Murine Monoclonal Antibodies to the tat Protein from Human Immunodeficiency Virus Type 1", J. Virol., 64:962-965 (February, 1990)	
CU		HARLOW et al, "Antibodies, a Laboratory Manual, pp. 96-97 (1988)	
CV		J. HINKULA et al, "Recognition of Prominent Viral Epitopes Induced by Immunization with Human Immunodeficiency Virus Type 1 Regulatory Genes", J. Virol., 71(7):5528-5539 (July, 1997)	
CW		G. PILKINGTON et al, "Recombinant Human Fab Antibody Fragments to HIV-1 REV and TAT Regulatory Proteins: Direct Selection from a Combinatorial Phage Display Library", Mol. Immunol., 33(4/5):439-450 (1996)	

Examiner Signature 	Date Considered <u>07/06/03</u>
--	---------------------------------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.